Akebia Therapeutics
AKBA
90 hedge funds and large institutions have $209M invested in Akebia Therapeutics in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 11 closing their positions.
318% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $336K
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
43% more capital invested
Capital invested by funds: $146M → $209M (+$62.8M)
10% more funds holding
Funds holding: 82 → 90 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.24M |
| 2 |
First Manhattan
New York
|
+$6.76M |
| 3 |
VAM
Visium Asset Management
New York
|
+$4.53M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.55M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$14.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$969K |
| 3 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$908K |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$695K |
| 5 |
CCI
Columbus Circle Investors
|
-$627K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Walleye Trading
New York
| – | -$9K | -980 | Closed |
|
AKBA Hedge Fund Activity: Q4 2015 in Review
90 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2015, worth a combined $209M — up 43% from $146M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AKBA positions and 11 closed out — a net gain of 8 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $7.24M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $14.6M sold.
- 90 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2015, up from 82 in Q3 2015.
- Funds reported $209M of Akebia Therapeutics stock for Q4 2015, up 43% quarter-over-quarter.
- 19 funds opened new Akebia Therapeutics positions in Q4 2015 and 11 closed out, a net change of +8 holders.
- The largest Akebia Therapeutics buyer in Q4 2015 was Eagle Asset Management, an estimated $7.24M added.
- The largest Akebia Therapeutics seller in Q4 2015 was Novo Holdings A/S, an estimated $14.6M sold.
Based on aggregated 13F filings for Q4 2015.